Social Media for Pharmaceutical Companies
Most pharmaceutical companies underuse social not because they doubt the reach but because an always-on channel in a regulated category creates two standing risks: an unapproved claim published in real time, and an adverse event reported in a comment thread and missed. Both are process problems with known solutions.
In short
Hibridge runs social media and digital content programmes for pharmaceutical and healthcare organisations, covering corporate and disease-awareness channels, HCP-targeted content, community management with adverse-event escalation, paid social, and the governance model that keeps a live channel inside promotional code boundaries.
What we do
Regulated-industry social, with the review trail built in.
Channel strategy and governance
What each channel is for, what can be said on it, who approves, and what happens when something unexpected appears.
Disease awareness and corporate content
Non-promotional education, corporate reputation and employer-brand content, produced bilingually.
HCP-facing content
Gated and targeted content for verified healthcare professionals, sequenced against the wider omnichannel plan.
Community management
Moderation with a defined adverse-event and product-complaint escalation path, response-time SLAs, and a full audit log.
Paid social
Targeting, creative and measurement inside platform policy for health advertisers, which is stricter and changes more often than most teams track.
Adverse event workflow
A documented, trained escalation route from first comment to your pharmacovigilance inbox, with timestamps that survive an audit.
Approach
How we keep a live channel safe
01
Frame
Code positions and a pre-approved response library agreed before the channel goes live.
02
Produce
Content batched and pre-cleared, so publishing is scheduling rather than approving.
03
Monitor
Moderation against a defined escalation matrix with logged timestamps.
04
Report
Engagement plus a compliance log — escalations raised, response times, actions taken.
Why it matters
Digital now takes the clear majority of healthcare and pharma advertising spend, and social has overtaken linear television. The channel mix has already moved; governance is what lags.
76%
eMarketer ·
33,000+
IQVIA (ChannelDynamics, 33,000+ HCPs across 38 countries) ·
Sources
Every figure on this page is attributed to its original publisher. Where a figure is organiser-reported or secondary, we say so.
Frequently asked questions
- How do you handle adverse events reported in comments?
- With a documented escalation route agreed with your pharmacovigilance function before launch: identification criteria, a response template, a defined handover window, and a timestamped log. Moderators are trained against that specific route, not a generic one.
- Can pharmaceutical companies run paid social in Egypt?
- Yes, within both the local promotional code and the platform’s own health advertising policies, which restrict targeting and creative independently of local law. Both constraints have to be cleared, and platform policy changes more often.
- Do you produce Arabic content, or translate it?
- Produce. Health content translated from English reads as translated and performs accordingly. We write in Arabic and review it against the same code positions.
Related services
Conference & Event Management
Congresses, symposia and advisory boards, run to pharma standards.
Conferences & EventsGo-To-Market & Product Launch
Launch sequencing built around what the market will actually reimburse.
Go-To-MarketPharmaceutical Marketing
HCP and patient programmes that survive review and move prescribing.
MarketingTell us what you are working on.
A launch, a congress, a portfolio that is not performing, or a compliance process that has become the bottleneck. We reply within one business day.